Eppin Pharma is a pharmaceutical company focused on creating a short-term, non-hormonal male birth-control pill. Its lead candidate is a small organic compound that binds to the EPPIN protein on the surface of sperm, rendering the sperm unable to function while leaving sperm production unaffected. The treatment is designed to be fast-acting and reversible, offering men an alternative to condoms and vasectomies. The company is now preparing for first-in-human clinical trials and will use new funds to establish proof-of-concept for safety and feasibility. Male Contraceptive Initiative (MCI) previously provided Eppin Pharma with a grant in 2019 to advance the science. The latest investment deepens that partnership and underscores the potential to revolutionize family planning by giving men additional contraceptive options. No operating metrics such as revenue or user numbers have been disclosed in the article.

Total raised

$1M

Funding rounds

1

Latest round

Equity

Latest activity

Jan 2023